Clinical trials of antiangiogenic therapy for hepatocellular carcinoma

被引：0
作者：
Akinobu Taketomi
机构：
[1] Hokkaido University,Department of Gastroenterological Surgery I, Graduate School of Medicine
来源：
International Journal of Clinical Oncology | 2016年 / 21卷
关键词：
Angiogenesis; Antiangiogenic therapy; Hepatocellular carcinoma; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.
引用
收藏
页码：213 / 218
页数：5
相关论文
共 111 条
[1]  
Taketomi A(2010)Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation Ann Surg Oncol 17 2283-2289
[2]  
Fukuhara T(2010)Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma Ann Surg Oncol 17 2740-2746
[3]  
Morita K(2015)Immunological landscape and immunotherapy of hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 12 681-700
[4]  
Taketomi A(2012)Hepatocellular carcinoma Lancet 379 1245-1255
[5]  
Toshima T(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[6]  
Kitagawa D(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
[7]  
Prieto J(2012)Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 821-829
[8]  
Melero I(2011)Management of hepatocellular carcinoma: an update Hepatology 53 1020-1022
[9]  
Sangro B(2012)EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 908-943
[10]  
Forner A(2014)An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma PLoS One 9 e112530-566
12345678910